NCT05647811View on ClinicalTrials.gov

Study of NM8074 in Adult C3 Glomerulopathy Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

July 31, 2027

Conditions
C3 Glomerulopathy
Interventions
DRUG

NM8074

NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Sponsors
All Listed Sponsors
lead

NovelMed Therapeutics

INDUSTRY

NCT05647811 - Study of NM8074 in Adult C3 Glomerulopathy Patients | Biotech Hunter | Biotech Hunter